Shares of Novo Nordisk NVO gained 5% on June 10, following a report that activist hedge fund Parvus Asset Management is building a stake in the company. Per the Financial Times, this London-based ...

Both CPAP and tirzepatide are acceptable treatments for comorbid obesity and OSA, with providers favoring CPAP and patients preferring tirzepatide.

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies, ...